Healx
More than 400 million people worldwide are impacted by 10,000 identified rare diseases, yet only 5 per cent of the diseases have approved treatment. Healx addresses this unmet need by combining its frontier AI technology with its drug discovery expertise to provide innovative accelerated solutions at scale.
In Q2 2024, Healx signed an investment agreement with its existing partner, Children’s Tumor Foundation (CTF), to advance Healx’s neurofibromatosis programme. Its lead candidate, HLX-1502, will enter a Phase 2 clinical trial In the months ahead.
In August 2024, Healx raised a $47m Series C round co-led by Silicon Valley-based R42 Group and Atomico, one of Europe’s largest VC firms. Since its launch, Healx has raised over $100 million with dozens of novel treatments in its therapeutic pipeline. In November, Healx unveiled a partnership with Sanofi to hunt new disease indications.
